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Human T-cell development is less well studied than its murine counterpart due to the 
lack of genetic tools and the difficulty of obtaining cells and tissues. Here, we report 
the transcriptional landscape of 11 immature, consecutive human T-cell developmental 
stages. The changes in gene expression of cultured stem cells on OP9-DL1 match those 
of ex vivo isolated murine and human thymocytes. These analyses led us to define evo-
lutionary conserved gene signatures that represent pre- and post-αβ T-cell commitment 
stages. We found that loss of dim expression of CD44 marks human T-cell commitment 
in early CD7+CD5+CD45dim cells, before the acquisition of CD1a surface expression. The 
CD44−CD1a− post-committed thymocytes have initiated in frame T-cell receptor rear-
rangements that are accompanied by loss of capacity to differentiate toward myeloid, 
B- and NK-lineages, unlike uncommitted CD44dimCD1a− thymocytes. Therefore, loss of 
CD44 represents a previously unrecognized human thymocyte stage that defines the 
earliest committed T-cell population in the thymus.
Keywords: human T-cell development, thymus, OP9-Dl1, T-cell commitment, cD44, multi-lineage potential, gene 
expression
inTrODUcTiOn
T-cell development in the thymus is a complex process that is accompanied by sequential transcrip-
tional and epigenetic changes leading to T-cell lineage commitment while suppressing alternative 
cell fates (1, 2). T-cell development has been extensively studied in mice, while in humans it is less 
well defined due to limited availability of thymus material and inherent genetic diversity. Research 
has focused on mimicking the thymus environment using in vitro differentiation cultures starting 
with hematopoietic stem cells (HSCs) isolated from human cord blood or bone marrow. Historically, 
human–mouse hybrid fetal thymic organ cultures (FTOC) have been used to functionally define the 
various stages of human T-cell development (3). Later, OP9-DL1 cocultures proved more useful to 
study T-cell differentiation (4). Expression of NOTCH1 ligands including the Delta-like 1 ligand on 
bone marrow-derived stromal cells from op/op M-CSF deficient mice (5) induces NOTCH signaling 
in target cells of the hematopoietic lineage. NOTCH signaling promotes T-cell differentiation while 
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inhibiting B-cell differentiation (6). The differentiation of HSCs 
in this coculture recapitulates human in vivo T-cell development 
as measured by the successive acquisition of CD7, CD5, CD1a, 
and CD4+CD8 surface markers (7, 8).
During development in the thymus, early T-cell precursors 
migrate within the cortex from which the positively selected 
CD4 and CD8 double positive (DP) thymocytes migrate to the 
medulla. As a result, developing thymocytes encounter specific 
signals at specific locations in the thymus (9). The OP9-DL1 
coculture system lacks the typical thymus architecture that is 
required for proper T-cell development. It supports the develop-
ment of early T-cell development until the DP stage. Yet, after pro-
longed culture few cells reach the CD4 and CD8 single-positive 
(SP) stage (10). These SP cells are functional and are generated 
independent of the presence of murine or human MHC class I 
expression on OP9-DL1 cells or the presence of dendritic cells; 
therefore, they have most likely been subject to positive selection 
based on interaction among T-cell precursors (11).
Early T-cell progenitors (ETPs) are uncommitted, multipotent 
thymocytes that retain the ability to develop into hematopoietic 
cells other than the T-cell lineage including NK-cells, B-cells, and 
cells of the myeloid and erythroid lineages (12–15). Fully com-
mitted thymocytes have lost multipotency and have undergone 
RAG1/2-mediated T-cell receptor (TCR) alpha and beta chain 
rearrangements. Based on earlier studies, human CD4/8 double-
negative (DN) thymocytes express CD1a at the proliferation stage 
when committed to the T-cell fate (16). The human HSC marker 
CD34 is gradually lost throughout development. However, CD34 
was demonstrated as a poor marker for “stemness” of uncom-
mitted thymocytes as it remains expressed (albeit dimly) on 
most CD1a+ T-cell committed thymocytes (13, 16, 17). Although 
upregulation of CD1a is generally used to define human T-lineage 
commitment (13), the human DN thymocyte maturation stages 
and the exact T-cell commitment point have not yet been clearly 
defined.
In this study, we generated gene expression profiles of early 
T-cells representing sequential human thymocyte differentiation 
stages. These have been derived from umbilical cord blood (UCB) 
stem/progenitor cells that have full multi-lineage differentiation 
potential and that were cultured on OP9-DL1 stromal cells. 
Comparisons of these in vitro-derived signatures with the gene 
signatures from in vivo normal murine and human early T-cell 
development stages in the thymus reveal strong conservation of 
pre- and post-T-cell commitment transcriptional profiles. From 
these analyses, we found that loss of human CD44 expression and 
loss of CD44 at the surface membrane of early DN thymocytes 
marks T-cell commitment. Commitment is validated by the 
initiation of TCRB recombinations and loss of potential for 
alternative cell fate decisions.
MaTerials anD MeThODs
human UcB and Thymus samples
Human UCB samples were obtained from consenting mothers 
after delivery at local hospitals. Mononuclear cells (MNCs) were 
isolated by Ficoll-Paque density centrifugation, washed, and 
frozen in 10% dimethyl sulfoxide and 90% fetal bovine serum 
(FBS) for later use. Thymi were obtained as surgical tissue dis-
cards from infants 2–9 months of age undergoing cardiac surgery 
at Erasmus MC Rotterdam, after informed consent from the par-
ents or legal guardians. The children did not have immunological 
abnormalities. Thymocytes were isolated by cutting the thymic 
lobes into small pieces and squeezing them through a metal mesh 
and stored at −80°C until further analyses. Informed consents 
were in accordance with the Institutional Review Board of the 
Erasmus MC Rotterdam and in accordance with the Declaration 
of Helsinki.
isolation of cD34+ cells from UcB
Frozen MNCs were thawed, washed, and labeled with MicroBeads 
conjugated to the monoclonal mouse anti-human CD34 antibody 
according to the manufacturer’s procedure (Miltenyi Biotec). 
The magnetic separation was performed twice using two MACS 
Columns (Miltenyi Biotec), consistently reaching a CD34+ purity 
of approximately 95%.
antibodies
Antibodies (with clone identification) used for flow cytometry: 
CD1a (HI149), CD3 (UCHT1), CD7 (M-T701), CD10 (HI10a), 
CD11b (ICRF44), CD13 (WM15), CD14 (MΦP9), CD20 (L27), 
CD22 (HIB22), CD33 (WM53), CD34 (8G12) (BD Biosciences), 
CD3 (BW264/56), CD4 (VIT4), CD5 (UCHT2), CD8 
(BW135/80), CD19 (LT19), CD33 (AC104.3E3), CD34 (AC136), 
CD44 (DB105), CD45 (5B1), CD56 (REA196), CD94 (REA113), 
CD123 (AC145) (Miltenyi Biotec).
OP9-Dl1 cocultures
OP9-DL1 cocultures were performed according to the original 
protocol (18). Briefly, CD34+ human HSC isolated from UCB was 
plated into 100 or 145 mm culture dishes (Greiner Bio-One B.V.), 
which were seeded with a monolayer of OP9-DL1 cells before-
hand. The α-minimal essential medium (Life Technologies) used 
for culture was supplemented with 20% FBS (Integro B.V.) plus 
10 U/mL penicillin, 10 µg/mL of streptomycin, and 0.025 µg/mL 
fungizone (PSF) (Life Technologies). Recombinant human stem 
cell factor (SCF) (10 ng/mL) (R&D systems), FLT3L (5 ng/mL) 
(Miltenyi Biotec), and interleukin-7 (IL7) (2  ng/mL) (Miltenyi 
Biotec) were added at the initiation of coculture and every 
2–3 days during transfer of HSC-derived cells onto new OP9-DL1 
plated cells. Cocultures were separated by vigorous pipetting and 
put through a 40-µm filter to reduce stromal cell line aggregates 
and eliminate contaminating OP9-DL1 cells.
Multi-lineage differentiation experiments were performed 
with the following modifications: recombinant human SCF 
(10 ng/mL), FLT3L (5 ng/mL), IL7 (5 ng/mL), and IL15 (10 ng/
mL) were added every 3–4 days to half of the medium that was 
refreshed without disturbing the cells. A continuous 10-day OP9-
coculture was initiated with 1,000 OP9 (-DL1, -GFP, or 1:1 mix) 
cells/well plated in 96-well plates 1 day before adding 4,000/well 
of the sorted thymocytes.
OP9-GFP and OP9-DL1 cell lines were kindly given to us by 
Dr. Zúñiga-Pflücker; the identity of the cell lines was confirmed 
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by DNA fingerprinting, and cells were regularly tested for myco-
plasma contamination.
TcrB rearrangements
In-frame Dβ–Jβ and Vβ–Jβ gene rearrangements were deter-
mined using the BIOMED-2 multiplex PCR and visualized using 
GeneScan (19). Primers for the Jβ1 cluster were hexachloro-
6-carboxy-fluorescein (HEX) labeled (blue traces), and primers 
for the Jβ2 cluster were 6-carboxy-fluorescein (FAM) labeled 
(green traces).
cell sorting and rna Preparation
Throughout the differentiation of HSC toward the T-cell lineage, 
we sorted T-cell fractions at various time points (days 0, 7, 12, 18, 
and 27) based on the expression of cell surface markers including 
CD45, CD34, CD7, CD5, CD1a, CD4, and CD8. Cell sorting 
purity was >98% and performed using the FACSAria II (BD 
Biosciences), flow cytometry was performed using the MACS 
Quant (Miltenyi Biotec), and data analysis was performed using 
the FlowJo software (Tree Star Inc.). Sorted populations (range: 
6.8 × 104–2.68 × 106 cells/population, median: 2.62 × 105 cells) 
were collected, washed twice in PBS, lysed in buffer RLT (Qiagen) 
plus 1/100 β-mercaptoethanol, and stored at −80°C. RNA was 
isolated using RNeasy Micro Kit according to the manufacturer’s 
protocol (Qiagen).
affymetrix gene expression arrays
The quality control, RNA labeling, hybridization, and data extrac-
tion were performed at ServiceXS B.V. (Leiden, the Netherlands). 
RNA concentration was measured using the Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies). The RNA quality 
and integrity was determined using Lab-on-Chip analysis on 
the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) and/
or on the Shimadzu MultiNA RNA analysis chips (Shimadzu 
Corporation). Biotinylated cRNA was prepared using the 
Affymetrix 3′ IVT Express Kit (Affymetrix) according to the 
manufacturer’s specifications with an input of 100  ng total 
RNA. The quality of the cRNA was assessed using the Shimadzu 
MultiNA in order to confirm if the average fragment size was 
according to Affymetrix’ specifications. Per sample, 7.5 µg cRNA 
of the obtained biotinylated cRNA samples was fragmented 
and hybridized in a final concentration of 0.0375 µg/µL on the 
Affymetrix HT HG U133+ PM (Affymetrix). After an automated 
process of washing and staining by the GeneTitan machine 
(Affymetrix) using the Affymetrix HWS Kit for GeneTitan (part 
nr. 901530), absolute values of expression were calculated from 
the scanned array using the Affymetrix Command Console v3.2 
software.
The data discussed in this publication have been deposited 
in NCBI’s Gene Expression Omnibus (20) and are accessible 
through GEO Series accession number GSE79379.1
1 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79379.
Taqman array Microfluidic cards
Reverse-transcriptase (RT) reactions (Promega) were performed 
to convert mRNA into cDNA. The real-time PCR (qPCR) reac-
tions were performed by Taqman Custom arrays that were pre-
designed according to the manufacturer instructions (Applied 
Biosystems). TaqMan gene expression assay targets were based 
on selected primers that were pre-loaded into each of the wells of 
a 384-well Taqman array card. TaqMan Gene Expression Assays 
consist of a pair of unlabeled PCR primers and a TaqMan probe 
with a FAM or VIC dye label on the 5′ end and minor groove 
binder and non-fluorescent quencher on the 3′ end. For the 
reaction, cDNA samples were diluted and mixed in 1:1 ratio with 
Taqman Fast Universal PCR Master Mix (Applied Biosystems). 
Relative levels of gene expression are determined from the 
fluorescence data generated during PCR using the 7900HT Fast 
Real-Time PCR System Relative Quantitation software (Applied 
Biosystems).
Bioinformatics
Affymetrix gene expression CEL files were processed using 
Partek® Genomics Suite® 6.6. Robust Multi-array Average (21) 
was applied prior to further analysis. In brief, the intensity 
levels were quantile normalized after background correction. 
Probeset-level expression values were summarized by median 
polish approach and eventually log2 transformed. Probesets were 
filtered for high variance (top 5%) and log2 expression values 
(>8), which resulted in 2,179 probesets. Using the annotation 
file of the array, these probesets were then summarized into 
1,387 genes by taking the median of all probesets across a gene. 
Principal component analysis (PCA) and hierarchical clustering 
were done using Partek® Genomics Suite® 6.6. Log2 expression 
values were standardized into z-scores prior to the clustering 
analysis. Pearson dissimilarity and Euclidean distance were used 
as distance metric. Gene set enrichment analysis (GSEA) (22) 
was performed using GSEA software downloaded from Broad 
Institute.2 GSEA is broadly used to analyze genome-wide expres-
sion profiles from samples belonging to two classes, in order to 
determine whether an a priori defined set of genes is correlated 
with the phenotypic class distinction. The method derives its 
power by focusing on gene sets instead of single genes. In this 
study, we took an unbiased approach at defining the gene sets 
using an unsupervised clustering method. For the OP9-DL1 
in  vitro dataset, the GSEA input gene list consisted of 1,387 
genes that were grouped into the 16 gene signatures identified 
by the clustering analysis. The T-cell populations were denoted 
as early or late T-cell program according to their gene expression 
profile similarities during T-cell differentiation. Gene sets with 
false discovery rate (FDR) q ≤ 0.25 were considered significantly 
correlated to the class distinction (22). The murine in vivo micro-
array data was obtained through access to the Immunological 
Genome Project data, GEO accession code: GSE15907 (23). 
For analysis of this in  vivo dataset, the GSEA input gene list 
consisted of 547 genes enclosed in the 5 signatures that form 
2 http://www.broadinstitute.org/gsea.
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the T-cell development gene expression signature. The human 
in  vivo microarray data were obtained from Dik et  al. (16), 
MIAME accession no. E-MEXP-337. Hierarchical clustering on 
the human thymocyte populations was performed using 399 out 
of 547 genes from the T-cell development gene signature. The 
remaining 148 genes could not profiled in the human dataset 
because the U133A array used in Ref. (16) contains fewer probe-
sets than the U133 plus 2.0 array used by us.
Relative levels of gene expression data generated by the 
Taqman array microfluidic cards were processed using Partek® 
Genomics Suite® 6.6. The sorted in vitro populations (A–F) were 
subject to ANOVA analysis to remove day and pool effects prior 
to the hierarchical clustering. Standardized z-scores of the expres-
sion values in 47 selected T-cell development genes were clustered 
using Pearson dissimilarity measure and average linkage. These 
47 genes are a subset of the 1,387 genes with high variation and 
expression levels in our in  vitro T-cell differentiation dataset. 
The same genes and clustering method were used for the human 
thymocyte populations (I–III) dataset. For this dataset, the 
expression values obtained by the microfluidic cards were subject 
to quantile normalization before further analysis.
resUlTs
consecutive stages of human In Vitro 
T-cell Differentiation represent  
Two Major gene signatures
We isolated CD34+ HSCs from human UCB and cultured these 
cells on OP9-DL1 stromal cells to induce T-cell differentiation. 
At various time points during 27-day cocultures (performed 
in biological triplicate), seven distinct T-cell populations were 
sorted as progeny from pooled CD34+ HSCs from multiple 
cord blood donors (Figure  1A). Microarray gene expression 
analysis was performed on 26 OP9-DL1-generated T-cell 
populations collected from five independent cocultures and 
three CD34+ HSC starting pools. PCA revealed three distinct 
clusters (Figure S1A in Supplementary Material). After filtering 
for probes with high variance (top 5%) and high log2 expres-
sion (>8), the expression profile was trimmed to 1,387 genes 
(2,179 probesets) that robustly separate the three PCA clusters 
(Figure  1B; Table S1 in Supplementary Material). One cluster 
(upper left corner) represents the gene expression profile of 
CD34+ cells. The other two developmental clusters characterize 
“early” T-cell progenitor (ETP) populations (including the CD7+ 
and part of the CD7+CD5+ sorted populations) and “late” T-cell 
differentiation populations (part of the CD7+CD5+ population 
and CD7+CD5+CD1a+, CD4/8 DP, and SP sorted populations). 
The “early” and “late” clusters represent a major change in the 
transcriptional program (Figures 1B,C). Of note, the CD7+CD5+ 
population (in orange) is divided over both clusters (Figure 1B); 
those fractions that were sorted on days 7 and 12 of the coculture 
cluster with early CD7+ populations, whereas those sorted on 
day 18 fall in the “late” cluster. Therefore, this CD7+CD5+CD1a− 
population is not one homogeneous population but reflect two 
distinct differentiation stages that dramatically differ in their 
transcriptional programs.
The 1,387 genes of our expression profile can be further dif-
ferentiated into 16 different gene signatures of co-expressed genes 
(Figures 1C,D; Table S1 in Supplementary Material). Based on 
GSEA, we identified five signatures (#2, #7, #8, #15, and #16) that 
are most differentially expressed between the early and late T-cell 
differentiation populations (Figure 1E). Signatures #7 and #8 are 
enriched for genes that are highly expressed in the early T-cell 
progenitor stages but downregulated at later T-cell differentiation 
stages. Signatures #2, #15, and #16 are enriched for genes that 
become expressed at later T-cell differentiation stages. These 
five gene signatures—comprising 547 genes in total—faithfully 
distinguish the early and late T-cell differentiation populations 
(Figures S1B,C and Table S1 in Supplementary Material). Early 
T-cell differentiation signatures #7 and #8 include transcription 
(co)factors that are important for HSC/ETP maintenance and/or 
lineage determination, such as MEIS1, LMO2, MEF2C, LYL1, and 
HHEX (24–26). Genes encoding transcription factors that are 
responsible for T-cell identity (including GATA3, TCF7, BCL11B, 
Figure S2 in Supplementary Material) and TCR rearrangements 
(RAG1/2) are present in late signatures #2, #15, or #16. Therefore, 
these five signatures contain essential genes that are associated 
with transcriptional programs required for stem/progenitor 
identity, T-cell specification, and lineage commitment.
The In Vitro gene expression signatures 
recapitulate In Vivo signatures of  
Pre- and Post-T-cell committed 
Thymocytes
We then compared our gene expression signatures to those of 
murine and human ex vivo sorted thymocyte subsets (16, 23, 25). 
We performed GSEA to determine the enrichment of our five 
gene signatures in the dataset of consecutive T-cell development 
populations from murine thymi, generated by the Immunological 
Genome Consortium (23). As a result, we demonstrate that our 
“early” signatures #7 and #8 are significantly enriched for genes 
that are typically expressed in uncommitted murine subsets 
ranging from long-term HSCs to DN1–DN2a stages (Figure 2A; 
FDR-corrected p-value is q <  0.001). Known pre-commitment 
genes such as HHEX, KIT, MEF2C, LYL1 are among the top 10 
genes in our early signatures (Figure 2A: left panel; Table S2 in 
Supplementary Material). Our “late” T-cell development gene 
signatures #2, #15, and #16 are significantly enriched for genes 
expressed in post-committed murine thymocyte subsets (DN2b 
and later subsets) and include BCL11B, TCF7, LEF1, GATA3 and 
various molecules associated with TCR signaling (FDR q = 0.028, 
Figure 2A: right panel; Table S2 in Supplementary Material). We 
then compared our gene signatures to gene expression data of 
human ex vivo sorted thymocyte populations (16). Interestingly, 
our gene signatures that discriminate pre- and post-commitment 
also divide the ex vivo sorted human thymocytes into uncommit-
ted (the CD1a− populations) and T-cell committed populations 
(CD1a+ and beyond; Figure  2B; Table S3 in Supplementary 
Material). These results show that the pre- and post-commitment 
programs in murine and human in  vivo T-cell development 
remain highly conserved in T-cells that are generated from HSCs 
cultured on OP9-DL1 stromal support.
FigUre 1 | continued
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consecutive stages of human early in vitro T-cell differentiation represent two major gene signatures. (a) Schematic representation of the OP9-DL1 
coculture with the sorting strategy of consecutive T-cell differentiation stages. The table displays the sorted populations (and the replicates, from a total of five 
cocultures) based on surface markers (CD45, CD34, CD7, CD5, CD1a, CD4, CD8) and number of days in coculture. All populations were also gated for CD45+GFP− 
to exclude OP9-DL1 cells that are GFP positive. (B) Principal component analysis of 29 samples based on the 2,179 probesets with high variance (top 5%) and log2 
expression values (>8). These probesets were summarized into 1,387 genes by taking the median of all probesets across a gene. UCB-derived CD34+ stem cells 
(dark blue, upper left corner), an early, and a late population can be distinguished. (c) Hierarchical clustering analysis using 1,387 genes (see Table S1 in 
Supplementary Material). Pearson dissimilarity measure and average linkage were applied to cluster the samples, and Euclidean distance and Ward’s method were 
applied to define 16 distinct gene signatures with similar expression patterns. (D) Average expression pattern of genes in the 16 gene signatures; some example 
genes are displayed. z-scores are on the y-axis and 29 populations on the x-axis, ordered according to Figure 1c. The gray area represents 1SD. (e) Gene set 
enrichment analysis on the in vitro T-cell differentiation dataset to select gene signatures that are significantly enriched in the early or late T-cell program (marked in 
green and bold). The Normalized Enrichment Score (NES) and false discovery rate (FDR) q-value for each gene signature are given on top of each sub-figure. 
Populations belonging to the early/late T-cell program were determined according to Figure 1c. Gene sets with FDR q ≤ 0.25 were considered significantly 
correlated to the class distinction (22).
FigUre 1 | continued
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loss of cD44 surface expression Marks 
T-cell commitment in early human 
Thymocytes
Further examination of the genes that are expressed in the 
ex vivo CD34+CD1a− human thymocyte populations (16) 
revealed expression of certain post-commitment genes [includ-
ing PTCRA, RAG1, RAG2, and DNTT (known as TDT)]. This 
suggests that thymocytes prior to their acquisition of CD1a 
surface expression have initiated TCRB rearrangements and 
are already committed to the αβ T-lineage (Figure  2B; Table 
S3 in Supplementary Material). From our gene signatures, we 
searched for surface antigens that are differentially expressed 
between pre- and post-commitment stages. We observed that 
expression of CD44, CD33, CD63, CD69, and CD300LF were 
markedly reduced before the appearance of CD1a on the cell 
surface (Figure 1D; Figure S2 in Supplementary Material). As 
the DN2a–DN2b T-cell commitment point in murine T-cell 
development is associated with an initial reduction of CD44 
expression (2, 23), we investigated whether loss of CD44dim 
surface expression marks human T-cell commitment. CD44 
surface expression on differentiating T-cells in the OP9-DL1 
system is lost from CD5+ T-cells before these acquire CD1a 
expression (Figure  3A). We sorted subsets at days 12 and 18 
from two independent OP9-DL1 cocultures with the inclu-
sion of CD44 as an additional sorting marker and were able to 
purify CD5+CD44dimCD1a− (E1), CD5+CD44−CD1a− (E2), and 
CD5+CD44−CD1a+ (F) populations (Figure  3A). Microfluidic 
cards-based RT-qPCR analysis of 47 pre- or post-commitment 
genes strongly supported a pre-commitment profile in sorted 
populations A through E1, and a T-lineage commitment profile 
in populations E2 and F (Figure 3B). Therefore, T-cell commit-
ment of differentiating T-cells cultured on OP9-DL1 is associ-
ated with loss of CD44dim expression before the acquisition of 
CD1a surface expression.
Next, we determined whether loss of CD44 during in  vitro 
T-cell differentiation from UCB-derived CD34+ stem cells paral-
lels T-cell commitment during in vivo human T-cell development. 
For this, we first assessed CD44 expression in human thymocytes 
in relation to surface expression levels of CD45, CD3, and other 
T-cell markers (Figure 4). CD44 expression on early, uncommit-
ted thymocytes is dim in comparison to the bright CD44 expres-
sion on mature T-cells (27), and roughly correlates with CD45 
expression levels (Figure  4). CD45dim thymocytes are CD44dim 
or CD44− and predominantly consist of developmentally early 
thymocyte fractions that include CD4/8 DN, CD4 immature 
single positive (ISP), and some CD3− DP cells. The DN thy-
mocytes contain the CD44dim, CD44−CD1a−, and CD44−CD1a+ 
populations, whereas the later CD4ISP and immature CD3− DP 
cells are all CD44−CD1a+ (Figure  4). In contrast CD45bright 
thymocytes are CD44bright and mostly consist of CD3+ DP, CD4 
SP, and CD8 SP thymocyte populations. The human thymus also 
contain very low numbers of mature B-, myeloid, and NK-cells 
(17), that are CD3/4/8 triple-negative but CD45brightCD44bright, 
and CD1a− (Figure 4).
We then sorted immature (CD34+)CD7+CD5+ thymocytes 
from CD45dim cells (lacking CD45brightCD44bright cells) from 
thymi of four independent and immunologically healthy 
donors. Following depletion of CD3, CD4, CD8, and CD19 
cells, CD7+CD5+CD45dim immature thymocytes were further 
sorted into three populations: CD44dimCD1a− cells (population 
I), CD44−CD1a− cells (population II), and CD44−CD1a+ cells 
(population III; Figure  5A). These ex vivo-sorted populations 
I–III are equivalent to the in  vitro populations E1, E2, and F 
(Figure  3A). Hierarchical cluster analysis of the gene expres-
sion levels of the panel of 47 pre- and post-commitment genes 
identifies population I (CD44dim) as uncommitted thymocytes, 
whereas populations II and III CD44− thymocytes have commit-
ted to the T-cell lineage (Figure 5B). Therefore, loss of CD44dim 
expression marks the transition to human T-cell commitment 
in vivo, consistent with our in vitro data. Of note, expression of the 
stem-cell marker CD34 gradually decreased in populations I–III 
but was still present on a fraction of CD1a+ thymocytes (popula-
tion III, Figure 5A), in line with previous observations (13, 16). 
Therefore, loss of CD34 surface expression does not mark T-cell 
commitment.
loss of cD44 Functionally Marks  
human T-cell commitment
αβ T-cell committed thymocytes have initiated or completed 
TCRB gene rearrangements. To further validate T-cell commit-
ment in sorted CD44−CD1a− (population II) and CD44−CD1a+ 
(population III) human thymocytes, we analyzed Dβ–Jβ and Vβ–
Jβ recombination events using GeneScan analysis (19). Analysis 
of sorted CD44dim uncommitted thymocytes (population  I) 
FigUre 2 | The in vitro gene expression signatures recapitulate in vivo signatures of pre- and post-T-cell committed thymocytes. (a) Gene set 
enrichment analysis of our in vitro gene signature on the gene expression dataset of consecutive T-cell development populations from murine thymi (see Table S2 in 
Supplementary Material). The first and second sub-figures from the left are the analysis results using gene signatures #7 and #8. The Normalized Enrichment Score 
(NES), Nominal p-value, and false discovery rate q-value indicate that these two gene signatures correlate with the pre-commitment stages. Also shown in the first 
sub-figure is the list of top 10 input genes with the highest signal-to-noise ratios in this dataset. The third and fourth sub-figures are the same analysis for gene 
signatures #2, #15, and #16, which correlate with the post-commitment stages. (B) Hierarchical clustering (Euclidean distance and Ward’s method) on human 
thymocyte populations was performed using 399 out of the 547 in vitro pre-/post-commitment signature genes (see Table S3 in Supplementary Material); the 
remaining 148 genes were not profiled because they were not on the HG-U133A array used in the dataset in Ref. (16). The dendrogram on the left shows the 
clustering of different sorted human thymocytes, separating the pre- and post-committed populations.
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did not reveal detectable rearrangements (Figure  6A). In 
contrast, incomplete Dβ–Jβ and Vβ–Jβ recombination events 
were identified in the earliest population of post-committed 
CD44−CD1a− thymocytes (II) with a more complete spectrum 
of full recombinations present in CD44−CD1a+ thymocytes (III) 
(Figure 6A).
To provide functional evidence that loss of CD44dim marks 
T-cell commitment, we investigated the intrinsic potential of 
alternative cell fate decisions in the three sorted human thymo-
cyte populations I–III. For this, thymocytes from populations 
I–III were cultured on OP9-DL1 stromal cells, on OP9-GFP 
control cells that do not support T-cell differentiation or on a 
FigUre 3 | loss of cD44 surface expression marks T-cell commitment in vitro. (a) Sorting strategy for isolating T-cell differentiation stages A–F from 
duplicate (n = 2) 12- and 18-day cocultures started with pooled CD34+ hematopoietic stem cells, based on surface markers CD45, CD34, CD7, CD5, CD1a, and 
CD44. (B) Hierarchical clustering (Pearson average) of sorted populations A–F using 47 selected T-cell development genes. Expression values were obtained by 
Taqman array microfluidic cards, followed by ANOVA to remove day and pool effects.
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1:1 mixture of OP9-DL1/OP9-GFP stromal cells. These cultures 
were performed in the presence of cytokines that support dif-
ferentiation into various hematopoietic lineages. After seven 
days of coculture, microscopic inspection already revealed 
the inability of committed thymocyte populations II and III to 
proliferate in cocultures with OP9-GFP stromal cells (Figure S3 in 
Supplementary Material). After 10 days of coculture under various 
stromal support conditions, we determined the total numbers of 
T-, NK-, B-, and myeloid cells based on lineage markers CD5 and 
CD1a (T), CD56 and CD94 (NK), CD19 (B), and CD33 (myeloid) 
FigUre 4 | cD45bright are mature and cD45dim are immature human thymocytes, correlating with the intensity of cD44 expression. Human 
thymocytes were thawed and stained directly (a) or after CD3, CD4, and CD8 (partial) depletion of ~95% of all thymocytes (B) with various antibodies as 
indicated.
10
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FigUre 5 | loss of cD44 surface expression marks T-cell commitment in early human thymocytes. (a) Sorting strategy for isolating T-cell developmental 
stages I–III from four independent donors (n = 4), based on CD45, CD7, CD5, CD1a, and CD44 after pre-depletion of CD3-, CD4-, CD8-, and CD19-expressing 
thymocytes. (B) Hierarchical clustering (Pearson average) of sorted populations I–III using 47 selected T-cell development genes. Expression values were obtained 
by Taqman array microfluidic cards, followed by quantile normalization.
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(Figures  6B,C). The uncommitted thymocytes (population I) 
proliferated well and differentiated into cells of all four lineages 
on OP9-DL1 support. This uncommitted population efficiently 
gave rise to B-, myeloid, and NK-cells—but not T-cells—when 
cultured on OP9 control cells. In contrast, committed thymocyte 
populations II and III gave rise to CD5+CD1a+ T-cells only, 
indicating that these populations have lost the potential to dif-
ferentiate into alternative cell fates (Figure 6C). The fact that both 
populations II (CD44−CD1a+) and III (CD44−CD1a−) have fully 
adopted the T-cell fate illustrates that loss of CD44—rather than 
the acquisition of CD1a—is the first surface marker that identifies 
post-committed human thymocytes.
DiscUssiOn
The early stages of human T-cell development have been 
investigated (28) without or with gene expression profiling 
(16), using FTOC cultures (3, 29, 30), and more recently cocul-
tures on OP9-DL1 (11). During the last decade, the OP9-DL1 
in  vitro coculture system has been used widely to study T-cell 
development (31). The use of human hematopoietic progenitors 
in this culture system offers a relatively easy and efficient tool 
to translate studies from in  vivo mouse models to the human 
situation (11). Sequential acquisition of T-cell specific surface 
markers recapitulates T-cell development from bone marrow 
or cord blood hematopoietic progenitors to the DP stage (8). 
Here, we have sorted subsets at different stages during early 
T-cell differentiation and demonstrated conservation of early 
T-cell transcriptional profiles including pre- and post-T-cell 
commitment programs compared to in vivo mouse and human 
T-cell development. We identified loss of CD44dim expression in 
immature, CD45dim thymocytes as a marker for T-cell commit-
ment that precedes acquisition of CD1a. Our results demonstrate 
that CD44−CD1a− thymocytes have initiated TCR Dβ–Jβ and 
Vβ–Jβ rearrangements and are T-lineage restricted. These results 
explain why the CD34+CD1a− thymocyte population from previ-
ous studies—considered to be uncommitted thymocytes—is in 
fact heterogeneous with mixed CD44dim and CD44− expression 
(8, 16). The multi-lineage potential of CD34+CD44+ human thy-
mocytes has been suggested (27), but this study did not consider 
FigUre 6 | loss of cD44 functionally marks human T-cell commitment. (a) GeneScan visualization of in-frame Dβ–Jβ (left column) and Vβ–Jβ (middle and 
right columns) gene rearrangements, determined using the BIOMED-2 multiplex PCR (19). One representative example of three independent donors is shown. 
Healthy peripheral blood mononuclear cells were used as a positive, polyclonal control (top row); populations I–III are indicated (rows 2–4). Primers for the Jβ1 
cluster were hexachloro-6-carboxy-fluorescein-labeled (blue traces), and primers for the Jβ2 cluster were 6-carboxy-fluorescein (FAM)-labeled (green traces). Red 
traces: internal size markers. (B) Flow cytometry analysis of sorted human thymocyte populations I–III after 10 days of coculture on OP9-DL1:GFP mixed cells. 
Differentiation into various hematopoietic lineages is defined as follows: T-lineage (blue): CD5+CD1a+, NK-lineage (red): CD56+CD94+, B-lineage (yellow): CD19+, 
myeloid lineage (green): CD33+. During differentiation, all populations remain CD45+ and CD7+. (c) Absolute cell numbers ± SD of each differentiated and 
proliferated hematopoietic lineage from a representative of three experiments, after 10 days of coculture on a layer of OP9-DL1, a 1:1 mix, or OP9-GFP (ctrl.) cells. 
The number of cells from populations I–III used to initiate the cocultures on day 0 was 4,000 cells/well, indicated by the dashed horizontal line.
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CD44dim expression. Our study places CD44dim expression in 
the context of other T-cell development markers in immature 
CD45dim thymocytes and provides first functional evidence that 
loss of CD44dim marks human T-cell commitment in vivo.
Similar to human early T-cell development, the major 
transcriptional change in murine T-cell development—well 
before the DP stage—segregates uncommitted from αβ T-cell 
committed thymocytes (2, 23). In murine thymocytes, this 
well-characterized transition occurs in the second CD4/8 DN 
stage (DN2; CD44+CD25+), before the TCRβ checkpoint in 
DN3 (CD44−CD25+) (14, 32). T-cell commitment is defined 
by the transition from DN2a to DN2b that is marked by the 
initial reduction of CD44 surface expression (2, 23). This 
reduction of CD44 expression in mice is conserved in humans 
(from CD44dim to CD44−) and marks T-cell commitment. This 
suggests conservation of a functional role for CD44 in uncom-
mitted thymocytes. CD44 is an glycosylated adhesion and 
migration molecule with several isoforms due to alternatively 
spliced exons in the extracellular domain (33). The standard 
CD44 isoform (CD44s) is expressed on hematopoietic (stem) 
cells (as well as many other cell types) and is required for HSC 
niche formation and quiescence during early hematopoietic 
FigUre 7 | schematic comparison of human and mouse early T-cell development in the thymus. Bone marrow-derived lymphoid progenitors enter the 
thymus (depicted as a blue oval) and exhibit dim CD44 expression. T-cell commitment is marked by the downregulation of CD44. As cells mature, they regain CD44 
expression.
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development. In addition to its expression on hematopoietic 
stem/progenitor and ETP cells, CD44 is highly re-expressed on 
mature lymphocytes (Figure 7) and functions in the homing to 
secondary lymphoid organs. In the thymus, laminin-5-induced 
CD44 cleavage by metalloproteinase-14 also directs the migra-
tion of mature thymocytes within the medulla as well as the 
exit from the medulla (34). The rare population of uncommitted 
CD44dim ETPs is present in subcapsular clusters in the cortex 
of the thymus, suggesting that CD44 also directs thymocyte 
precursors from the bone marrow to the thymus, entry into 
the thymus, and potentially intrathymic migration during early 
T-cell development (35, 36).
In T-cell acute lymphoblastic leukemia (T-ALL) and other 
T-cell malignancies, the relevance of CD44 expression is 
unknown. In light of the findings here, the CD44dim expression 
on normal uncommitted ETPs may represent the stage of the 
immature subtype of T-ALL also referred to as ETP-ALL, a 
subtype characterized by expression of many stem cell genes. 
In many other cancer types and leukemias, CD44 has gained 
clinical interest because CD44s and variant isoforms (CD44v) 
feature “stemness” potential. Currently, multiple anti-CD44-
based therapeutic approaches are investigated for their ability to 
target leukemia- or cancer-initiating cells (LIC/CIC) with this 
“stemness” potential (33).
By adding CD44, we have expanded the immunophenotypes 
of the different phases of early T-cell development in the human 
thymus (Figure 7). CD44dimCD45dim human thymocytes reflect 
uncommitted ETP cells that are mainly characterized by the 
expression of transcription factors from alternative blood 
lineages, multi-lineage potential, and the absence of TCRB 
rearrangements. Loss of CD44dim marks T-cell commitment that 
coincides with the upregulation of T-cell specific transcription 
factors (e.g., GATA3, BCL11B, TCF7), loss of alternative cell 
fate potential, and the initiation of TCRB rearrangements. Next, 
the thymocytes acquire CD1a and complete their TCRB rear-
rangements. In conclusion, combining CD44 and CD1a surface 
markers in CD45dim thymocytes (in addition to other markers) 
is important in the characterization of pre- and post-committed 
human thymocytes and will help to better understand human 
T-cell development and T-cell commitment.
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